Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors

This is an open-label, phase I-II dose-escalation and expansion study designed to define the recommended dose of brigatinib as monotherapy in pediatric and young adult patients with ALK+ ALCL, IMT or other solid tumors and to evaluate the pharmacokinetics (PK), (long-term) safety, and efficacy of brigatinib in these children.

Trial Details

NCT ID
NCT04925609
Phase
PHASE1 / PHASE2
Sponsor
Princess Maxima Center for Pediatric Oncology
Status
RECRUITING
Cancer Type
Non-Hodgkin Lymphoma Lymphoma
Interventions
  • Brigatinib
Locations (sample)
  • Paris, France|48.85341,2.3488
  • Utrecht, Utrecht, Netherlands|52.09083,5.12222

Key Eligibility Criteria

  • Patients must be 1 and \< 26 years of age at the time of enrollment, and able to swallow brigatinib tablets at the time of enrollment, with a minim…
  • Patients must have a confirmed diagnosis of cancer histologically at baseline. In patients where a repeat biopsy at relapse (or moment of refractor…
  • Patients are required to provide prior results showing an activating ALK aberration in the tumor per local laboratory results, and material needs t…
  • For Phase 1:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Hodgkin Lymphoma Lymphoma Trials on Trialify →